Literature DB >> 27365578

VIAGRA : IS IT A WONDER DRUG ?

J S Saini1, M K Garg2.   

Abstract

Male erectile dysfunction is common and frustrating after the age of forty years. Erectile dysfunction is a cause of misery, relationship difficulties, and significantly reduced quality of life. Sildenafil citrate (Viagra) has shown promising results in recently published clinical trials. Sildenafil is a potent and competitive inhibitor of cGMp specific phosphodiesterase-5, predominant isoenzyme in the human corpus cavernosum. It is effective in erectile dysfunction of diverse origin, however it requires a patent vascular system to be effective. It is not effective in patients with endocrinal impotence, loss of libido, premature ejaculation or infertility. Its main adverse effects are headache, flushing, dyspepsia, diarrhoea, nasal congestion, indigestion, visual disturbances, dizziness and rash. Ventricular tachycardia and acute myocardial infraction have been reported in patients of ischaemic heart disease after consumption of sildenafil. Six deaths have been reported in patients taking nitrates. In India it is likely to be prescribed by a primary care physician without complete evaluation of patient on complaint of impotence. Hence the ethical question of who should prescribe this drug should be addressed by medical fraternity and proper guidelines formulated to avoid misuse of sildenafil. Phosphodiesterase is distributed in nerve, central nervous system, and systemic vasculature, hence long-term effects of drug on these tissues has to be ascertained. It should be made mandatory to report all adverse drug reactions to ADR monitoring centres. It is a wonder for those who require it, but has potentially dangerous adverse effects and drug interactions and hence is and not a wonder pill for all kinds of impotence.

Entities:  

Keywords:  Erectile dysfunction; Impotence; Phosphodiesterase inhibitor; Sildenafil citrate

Year:  2011        PMID: 27365578      PMCID: PMC4925037          DOI: 10.1016/S0377-1237(01)80090-3

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  13 in total

1.  Need for monitoring adverse drug reactions.

Authors:  R P Nerurkar; M Y Nadkar; S K Bichile
Journal:  J Assoc Physicians India       Date:  1998-08

2.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

3.  Acute myocardial infarction associated with sildenafil.

Authors:  J Feenstra; R J van Drie-Pierik; C F Laclé; B H Stricker
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

4.  Viagra is licensed in Europe, but rationed in Britain.

Authors:  A Brooks
Journal:  BMJ       Date:  1998-09-19

Review 5.  NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.

Authors: 
Journal:  JAMA       Date:  1993-07-07       Impact factor: 56.272

Review 6.  Physiology of penile erection.

Authors:  K E Andersson; G Wagner
Journal:  Physiol Rev       Date:  1995-01       Impact factor: 37.312

7.  The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction.

Authors:  U Kurt; H Ozkardeş; U Altuğ; C Germiyanoğlu; M Gürdal; D Erol
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

8.  Sildenafil, a novel effective oral therapy for male erectile dysfunction.

Authors:  M Boolell; S Gepi-Attee; J C Gingell; M J Allen
Journal:  Br J Urol       Date:  1996-08

9.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

10.  Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study.

Authors:  F Montorsi; L F Strambi; G Guazzoni; L Galli; L Barbieri; P Rigatti; G Pizzini; A Miani
Journal:  Urology       Date:  1994-11       Impact factor: 2.649

View more
  1 in total

Review 1.  New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.

Authors:  Marian Cruz-Burgos; Alberto Losada-Garcia; Carlos D Cruz-Hernández; Sergio A Cortés-Ramírez; Ignacio Camacho-Arroyo; Vanessa Gonzalez-Covarrubias; Miguel Morales-Pacheco; Samantha I Trujillo-Bornios; Mauricio Rodríguez-Dorantes
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.